DRUG DISCOVERY PIPELINE
Since its inception in 2014, FNDR has generated a portfolio of therapeutics in tuberculosis, nontuberculosis mycobacteria, malaria, dengue, leishmania, bacterial infections, COVID-19 and RSV, spanning over early-stage discovery to late-stage clinical trials. Click here for FNDR's areas of research focus, our publications and information about our research programs.
RESPIRATORY SYNCYTIAL VIRUS
FNDR performs various preclinical in vitro and animal studies for BSL-2 and BSL-3 bacterial, fungal and viral pathogens under a fee-for-service mode to test therapeutics, vaccines, and other items. Click here for more information.
Drug in Clinical Development
Ongoing Innovation Projects on Infectious Disease Drug Discovery and Platform Technologies.
Repurposed drugs under development
Contract Research Projects Completed
New Drugs in Preclinical Development
Research and Development Partners
Scientists from Spain and India Lead an International Project to Develop New Antibiotics Against Gram-Negative Bacteria
8 September 2022
Foundation for Neglected Disease Research (FNDR), ABAC Therapeutics, together with the artificial intelligence (AI) company, Peptris, and with scientific support from Medicines for Malaria Venture (MMV), will collaborate in an international project to optimize a new chemical structure that has shown effectiveness against Gram-negative bacteria, the greatest current threat to public health. In recent decades, there has been a significant increase in the incidence of infections caused by the Gram-negative bacteria known as “the four killers”: Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli and Klebsiella pneumoniae. The team of researchers intends to identify and optimise molecules that could be progressed to clinical studies within the next two years.